Seer Inc
Change company Symbol lookup
Select an option...
SEER Seer Inc
SNCY Sun Country Airlines Holdings Inc
NCZ Virtus Convertible & Income Fund II
XPEV Xpeng Inc
PTON Peloton Interactive Inc
PEB Pebblebrook Hotel Trust
VFC VF Corp
BWG BrandywineGLOBAL ? Global Income Opportunities Fund
BPYPO Brookfield Property Partners LP
HLAHU Hamilton Lane Alliance Holdings I Inc
Go

Company profile

Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products. The Company’s initial product, the Proteograph product suite leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. The Proteograph product suite is an integrated solution that is comprised of consumables, an automation instrument, and software. Its approach is based on engineered NPs that enable unbiased sampling of intact proteins across the dynamic range of the proteome, capturing a myriad of molecular information at the level of protein variants as well as protein-protein interactions (PPIs). It is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The Company is initially focused on research applications for the Proteograph product Suite and are selling and marketing the Proteograph for research use only (RUO) eliminates the need for complex workflows required by other unbiased approaches.

Postmarket

Last Trade
Delayed
$6.86
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$6.86
Day's Change
0.40 (6.19%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
7.00
Day's Low
6.53
Volume
(Average)
Volume:
263,431

10-day average volume:
283,560
263,431

Company Profile

Seer, Inc. is a life sciences company. The Company is engaged in developing transformative products. The Company’s initial product, the Proteograph product suite leverages its engineered nanoparticle (NP) technology to provide large-scale access to the proteome. The Proteograph product suite is an integrated solution that is comprised of consumables, an automation instrument, and software. Its approach is based on engineered NPs that enable unbiased sampling of intact proteins across the dynamic range of the proteome, capturing a myriad of molecular information at the level of protein variants as well as protein-protein interactions (PPIs). It is focused on adoption of the Proteograph with customers in the proteomics and genomics markets. The Company is initially focused on research applications for the Proteograph product Suite and are selling and marketing the Proteograph for research use only (RUO) eliminates the need for complex workflows required by other unbiased approaches.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
29.00x
Price/Book (MRQ)
0.88x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

No historic growth available.

Short Interest

November 2022
Current Month
3.2M
Previous Month
3.2M
Percent of Float
5.77%
Days to Cover
10.7008 Days

Share Information

SEER is in a share class of common stock
Float
50.9M
Shares Outstanding
62.6M
Institutions Holding Shares
149
86.06%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Omid C. FarokhzadChmn.
  • David R. HornCFO
  • Elona KoganCounsel
  • Scott ThomasOther
  • David L. Hallal

Address

  • 3800 Bridge Parkway, Suite 102
  • Redwood City, CA 94065
  • Phone: (650) 453-0000
  • Fax: (302) 655-5049
  • https://seer.bio/

Insider Trading

During the most recent quarter, 8K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2022. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.